Remeglurant

Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.